Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 17/20 | 0.59 |
| ▸ | CA2 | P00918 | 17/20 | 0.59 |
| ▸ | CA9 | Q16790 | 11/20 | 0.59 |
| ▸ | CA12 | O43570 | 2/20 | 0.58 |
| ▸ | CA7 | P43166 | 2/20 | 0.58 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.58 |
| ▸ | CA3 | P07451 | 2/20 | 0.57 |
| ▸ | CA4 | P22748 | 1/20 | 0.56 |
| ▸ | CA6 | P23280 | 1/20 | 0.56 |
| ▸ | CA5A | P35218 | 1/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.56 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.56 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.50 |
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31487920 | 0.86 | CA2 (0.68) | CA1CA2CA9CA12CA7 | |
| SCHEMBL603929 | 0.80 | CA2 (0.55) | CA1CA2CA9CA12CA7 | |
| SCHEMBL603928 | 0.80 | CA2 (0.67) | CA1CA2CA9CA12CA7 | |
| SCHEMBL3530381 | 0.80 | CA2 (0.46) | CA1CA2CA9CA12CA7 | |
| SCHEMBL25214451 | 0.78 | CA2 (0.62) | CA1CA2CA9CA12CA7 | |
| SCHEMBL30460130 | 0.78 | CA2 (0.62) | CA1CA2CA9CA12CA7 | |
| SCHEMBL5151223 | 0.78 | CA1 (0.44) | CA1CA2CA9CA12CA7 | |
| SCHEMBL602631 | 0.76 | SOS1 (0.55) | CA1CA2CA9CA12CA7 | |
| SCHEMBL10575001 | 0.76 | CA1 (0.42) | CA1CA2CA9CA12CA7 | |
| SCHEMBL301718 | 0.75 | CA2 (0.69) | CA1CA2CA9CA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119219810-A | Ionic polymer and preparation method and application thereof | 佛山绿动氢能科技有限公司 | 2024-12-31 | — | — | CN | claimed |
| EP-4682148-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Ireland Unlimited Company (IE) | 2026-01-21 | — | — | EP | disclosed |
| US-20250161318-A1 | SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | ABBVIE INC (US) | 2025-05-22 | — | — | US | disclosed |
| CN-120005064-A | Aryl ion polymer and preparation method and application thereof | 佛山绿动氢能科技有限公司 | 2025-05-16 | — | — | CN | disclosed |
| US-20250019364-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2025-01-16 | — | — | US | disclosed |
| CN-119219809-A | Fluorine-containing polymer, preparation method thereof and ion exchange membrane | 佛山绿动氢能科技有限公司 | 2024-12-31 | — | — | CN | disclosed |
| CN-119219810-A | Ionic polymer and preparation method and application thereof | 佛山绿动氢能科技有限公司 | 2024-12-31 | — | — | CN | disclosed |
| EP-4474383-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Ireland Unlimited Company (IE) | 2024-12-11 | — | — | EP | disclosed |
| CN-118852135-A | N-acyl sulfonamide compound, preparation method, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2024-10-29 | — | — | CN | disclosed |
| CN-118063359-B | Binary asymmetric organic lithium salt, electrolyte and lithium battery | 蓝固(湖州)新能源科技有限公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-102448959-A | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBOTT LAB | 2012-05-09 | — | — | CN | disclosed |
| WO-2012058392-A1 | SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | ABBOTT LABORATORIES (US) | 2012-05-03 | — | — | WO | disclosed |
| US-20120108590-A1 | MELT-EXTRUDED SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | ABBOTT LABORATORIES (US) | 2012-05-03 | — | — | US | disclosed |
| EP-2435432-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | Abbott Laboratories (US) | 2012-04-04 | — | — | EP | disclosed |
| WO-2011149492-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2011-12-01 | — | — | WO | disclosed |
| US-20110124628-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2011-05-26 | — | — | US | disclosed |
| WO-2010138588-A9 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2011-05-05 | — | — | WO | disclosed |
| WO-2011029842-A1 | SULFONAMIDES AS INHIBITORS OF BCL-2 FAMILY PROTEINS FOR THE TREATMENT OF CANCER | NOVARTIS AG (CH) | 2011-03-17 | — | — | WO | disclosed |
| WO-2010138588-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | WO | disclosed |
| US-20100305122-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305122-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | CA1 1508/4885CA2 2479/4885CA9 3565/4885 |
| US-20250019364-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | CA1 1508/4885CA2 2479/4885CA9 3565/4885 |
| US-20120108590-A1 | MELT-EXTRUDED SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | BCL2, BAX, BCL2L1 | CA1 1868/4885CA2 1894/4885CA9 3380/4885 |
| US-20250161318-A1 | SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | BCL2, BAX, BCL2L1 | CA1 2706/4885CA2 3015/4885CA9 3917/4885 |
| US-20110124628-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | CA1 1290/4885CA2 2352/4885CA9 3298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.